Last reviewed · How we verify
Bispecific antibody for PD-L1 and VEGF-A — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Bispecific antibody for PD-L1 and VEGF-A (Bispecific antibody for PD-L1 and VEGF-A) — BioNTech SE.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bispecific antibody for PD-L1 and VEGF-A TARGET | Bispecific antibody for PD-L1 and VEGF-A | BioNTech SE | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bispecific antibody for PD-L1 and VEGF-A CI watch — RSS
- Bispecific antibody for PD-L1 and VEGF-A CI watch — Atom
- Bispecific antibody for PD-L1 and VEGF-A CI watch — JSON
- Bispecific antibody for PD-L1 and VEGF-A alone — RSS
Cite this brief
Drug Landscape (2026). Bispecific antibody for PD-L1 and VEGF-A — Competitive Intelligence Brief. https://druglandscape.com/ci/bispecific-antibody-for-pd-l1-and-vegf-a. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab